SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
Trial shows similar heart benefits for two diabetes medications
This systematic review and network meta-analysis compared SGLT2 inhibitors and GLP-1 receptor agonists for major adverse cardiovascular even…
Two common types of diabetes drugs both show significant reductions in major heart events for patients with a history of heart attacks.
SGLT2 inhibitors reduce body fat without significant impacts on skeletal muscle mass in type 2 diabetes
SGLT2 Inhibitors Reduce Fat Mass in Type 2 Diabetes Patients
This network meta-analysis of 5,399 patients evaluated the effects of SGLT2 inhibitors on body composition. The study found that while SGLT2…
New analysis shows SGLT2 inhibitors consistently reduce body fat and weight in adults with type 2 diabetes without significantly reducing mu…
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Initial dual oral therapy improves HbA1c target achievement in early stage type 2 diabetes
Dual Therapy Shows Better Results for Type 2 Diabetes Control
Researchers evaluated the efficacy of initial dual oral therapy compared to monotherapy for patients with early-stage type 2 diabetes. The f…
Starting with two medications instead of one may help people with early type 2 diabetes reach their blood sugar goals more effectively.
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
New management model improves medication use and health for seniors
This randomized controlled trial of 200 older adults with type 2 diabetes and atherosclerotic cardiovascular disease found that a general me…
A new personalized care plan helps older adults with diabetes and heart disease stay on their medications and improve their daily habits.
Finerenone reduces composite cardiovascular death and worsening heart failure events in patients with symptomatic heart failure
Finerenone Reduces Heart Failure Events in Specific Patient Groups
This narrative review evaluates finerenone for patients with symptomatic heart failure and LVEF ≥40%. It finds that finerenone reduces the c…
A new medication called finerenone may help reduce certain heart failure events for adults with specific types of heart muscle function.
SGLT2 inhibitors associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes
SGLT2 inhibitors associated with lower mortality in heart transplant patients
This meta-analysis examined the impact of SGLT2 inhibitor use on outcomes for heart transplant recipients with type 2 diabetes. The authors …
New analysis suggests SGLT2 inhibitors may lower death rates for heart transplant recipients with type 2 diabetes without increasing UTI ris…
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
All SGLT2 inhibitors Articles
- SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
- SGLT2 inhibitors reduce body fat without significant impacts on skeletal muscle mass in type 2 diabetes
- Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
- Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
- Initial dual oral therapy improves HbA1c target achievement in early stage type 2 diabetes
- General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
- Finerenone reduces composite cardiovascular death and worsening heart failure events in patients with symptomatic heart failure
- SGLT2 inhibitors associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes
- Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
- SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
- Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
- Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
- Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
- SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
- SGLT2 and dual SGLT1/2 inhibitors reduce cardiovascular death or heart failure hospitalization risk in type 2 diabetes patients
- Triple oral therapy with metformin, SGLT-2, and DPP-4 inhibitors lowers HbA1c better than dual regimens in adults with type 2 diabetes
- Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
- Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
- Meta-analysis finds SGLT2 inhibitors reduce cardiac arrest risk in CKD patients
- Combining finerenone with SGLT2 inhibitors lowers mortality and cardiovascular events in diabetic chronic kidney disease patients
- Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes
- Meta-analysis shows SGLT2 inhibitors reduce all-cause mortality in heart failure patients
- SGLT-2 inhibitors reduce heart failure hospitalization and stroke in patients with acute coronary syndrome
- Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes
- Meta-analysis and cohort study suggest association between SGLT2 inhibitors and reduced arrhythmia recurrence
- Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy
- Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
- Computational model review predicts dual optima for combination therapy in ageing
- Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD
- Systematic review links hypertension, diabetes, and pulmonary inflammation; SGLT2 inhibitors show potential
- Jordan guideline review highlights SGLT2 inhibitor access barriers for heart failure patients
- Narrative review supports SGLT-2i use in cardiovascular-kidney-metabolic syndrome
- Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
- Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
- Meta-analysis of 13 trials finds SGLT2 inhibitors reduce heart failure hospitalization in myocardial infarction
- Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
- Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
- SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
- Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
- Meta-analysis identifies risk factors for diabetic kidney disease in Asian patients with type 2 diabetes
- Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
- Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care
- FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
- FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
- Meta-analysis finds SGLT2 inhibitors reduce mortality and hospitalization in older heart failure patients
- Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
- Self-management and glycemic control linked to lower MCI risk in rural elderly with type 2 diabetes
- Structured exercise program improves glycemic control and fitness in Bangladeshi adults with type 2 diabetes
- SGLT2 inhibitors associated with lower mortality in ATTR-CM patients receiving disease-modifying therapy
- SGLT2 inhibitors reduce weight and fat mass in older adults with T2DM, with smaller muscle mass decline